Journal article icon

Journal article

Translating molecular advances in Down syndrome and Fragile X syndrome into therapies

Abstract:

Ongoing treatments for genetic developmental disorders of the central nervous system are mostly symptomatic and do not correct the genetic cause. Recent identification of common mechanisms between diseases has suggested that new therapeutic targets could be applied across intellectual disabilities with potential disease-modifying properties. The European Down syndrome and other genetic developmental disorders (DSG2D) network joined basic and clinical scientists to foster this research and car...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/j.euroneuro.2018.03.006

Authors


More from this funder
Name:
European College of Neuro Psychopharmacology
Grant:
DSG2D
More from this funder
Name:
National Institutes of Health
Grant:
NS088503
More from this funder
Name:
Spanish Ministry of Economy
Grant:
SAF2016-79956-R
More from this funder
Name:
DIUE de la Generalitat de Catalunya
Grant:
2014SGR 680
More from this funder
Name:
Investissements d'avenir
Grant:
ANR-10-IAIHU-06, ANR-10-IDEX-0002-02, ANR-10-LABX-0030-INRT, ANR-10-INBS-07 PHENOMIN
Publisher:
Elsevier
Journal:
European Neuropsychopharmacology More from this journal
Volume:
28
Issue:
6
Pages:
675-690
Publication date:
2018-06-07
Acceptance date:
2018-03-12
DOI:
EISSN:
1873-7862
ISSN:
0924-977X
Pmid:
29887288
Language:
English
Keywords:
Pubs id:
pubs:857658
UUID:
uuid:fc4ce56d-cde9-4d9f-92f4-4a72046d4e67
Local pid:
pubs:857658
Source identifiers:
857658
Deposit date:
2018-06-19

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP